Charles River Laboratories International, Inc. $CRL Shares Acquired by State of Alaska Department of Revenue

State of Alaska Department of Revenue increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2,268.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,781 shares of the medical research company’s stock after buying an additional 107,061 shares during the period. State of Alaska Department of Revenue owned about 0.23% of Charles River Laboratories International worth $32,977,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Amundi raised its stake in Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares during the period. Empyrean Capital Partners LP acquired a new position in Charles River Laboratories International during the 4th quarter worth $24,237,000. Ranger Investment Management L.P. bought a new position in shares of Charles River Laboratories International in the first quarter worth $12,198,000. Finally, Bank of America Corp DE grew its stake in shares of Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after purchasing an additional 54,500 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent analyst reports. Royal Bank Of Canada lifted their price objective on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Mizuho increased their target price on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the company a “neutral” rating in a research report on Friday, September 25th. Evercore set a $330.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 25th. Finally, Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $302.33.

Insider Activity

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 981 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $308.44, for a total value of $302,579.64. Following the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,482,671.08. This represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This trade represents a 12.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 91,971 shares of company stock valued at $26,033,968 in the last ninety days. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Price Performance

NYSE CRL traded up $5.40 on Thursday, reaching $307.40. 389,636 shares of the stock traded hands, compared to its average volume of 929,006. Charles River Laboratories International, Inc. has a 12 month low of $146.20 and a 12 month high of $333.30. The company has a market cap of $14.68 billion, a price-to-earnings ratio of -63.41, a P/E/G ratio of 2.79 and a beta of 1.40. The firm’s fifty day simple moving average is $288.02 and its 200 day simple moving average is $226.13. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.